Alejandro Godoy
Roswell Park Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alejandro Godoy.
Advances in Urology | 2012
Faris Azzouni; Alejandro Godoy; Yun Li; James L. Mohler
Despite the discovery of 5 alpha-reduction as an enzymatic step in steroid metabolism in 1951, and the discovery that dihydrotestosterone is more potent than testosterone in 1968, the significance of 5 alpha-reduced steroids in human diseases was not appreciated until the discovery of 5 alpha-reductase type 2 deficiency in 1974. Affected males are born with ambiguous external genitalia, despite normal internal genitalia. The prostate is hypoplastic, nonpalpable on rectal examination and approximately 1/10th the size of age-matched normal glands. Benign prostate hyperplasia or prostate cancer does not develop in these patients. At puberty, the external genitalia virilize partially, however, secondary sexual hair remains sparse and male pattern baldness and acne develop rarely. Several compounds have been developed to inhibit the 5 alpha-reductase isozymes and they play an important role in the prevention and treatment of many common diseases. This review describes the basic biochemical properties, functions, tissue distribution, chromosomal location, and clinical significance of the 5 alpha-reductase isozyme family.
The Prostate | 2009
Paula Sotomayor; Alejandro Godoy; Gary J. Smith; Wendy J. Huss
Cancer stem cells are defined by their self‐renewal and multi‐potential capabilities and are hypothesized to be the source of primary and recurrent cancers. The stem cell properties of self‐renewal and pluripotency in embryonic stem cells and germ cells are regulated by Oct4A, a splice variant of the POU5F1 (Oct3/4) gene, while the function of the alternative splice variant, Oct4B, is unknown. Rare cells that express Oct4 were identified in several somatic cancers, however, the differential contributions of the Oct4A and Oct4B variants were not determined.
The Prostate | 2011
Alejandro Godoy; Elzbieta Kawinski; Yun Li; Daizo Oka; Borislav A. Alexiev; Faris Azzouni; Mark A. Titus; James L. Mohler
A third isozyme of human 5α‐steroid reductase, 5α‐reductase‐3, was identified in prostate tissue at the mRNA level. However, the levels of 5α‐reductase‐3 protein expression and its cellular localization in human tissues remain unknown.
Cell Cycle | 2009
Grinu Mathew; Earl A. Timm; Paula Sotomayor; Alejandro Godoy; Viviana P. Montecinos; Gary J. Smith; Wendy J. Huss
The efflux of Hoechst 33342 by ATP-binding cassette protein G2 (ABCG2) membrane pump allows reproducible identification of a subpopulation of cells by flow cytometric analysis termed the “side population” (SP). The SP identified by constitutive Hoechst efflux contains the stem/progenitor cell population from bone marrow and many solid organs, including prostate. DyeCycle Violet (DCV) is a cell membrane permeable, fluorescent vital dye that intercalates into DNA and is a substrate for ABCG2-mediated efflux. Therefore, DCV was evaluated in this study as a tool for identification of the SP from prostate cancer cell lines and from freshly harvested human prostate tissue. SPs that demonstrated ABCG2-mediated efflux of DCV were identified in the human prostate cancer cell lines CWR-R1, DU-145, and RWPE-1, but not in the BPH-1, LAPC-4, or PC-3 cell lines. Additionally, a SP was identified in enzymatically disaggregated prostate tumors from Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) human benign prostate tissue, and human prostate cancer tissue. The causal role of ABCG2-mediated efflux of DCV in the identification of the SP was confirmed by loss of the SP by incubation with the specific inhibitor of ABCG2, Fumitremorgin C. Expression of ABCG2 in the SP cells was confirmed by qRT-PCR and immunofluorescence analysis. Consequently, DCV represents an important new tool for isolation of viable candidate stem cells/cancer stem cells as a SP from cultured prostate cell lines, and prostate tissue specimens, without the requirement for instrumentation with ultra-violet excitation capability and minimizing the risk of damage to DNA in the sorted population.
Journal of Cellular Biochemistry | 2012
Karin Reinicke; Paula Sotomayor; Pedro Cisterna; Carolina Delgado; Francisco Nualart; Alejandro Godoy
Over‐expression of hexose transporters (Gluts), specifically Glut‐1, is a common event in human malignancies. In prostate cancer (CaP), however, expression of Gluts has been characterized poorly. In this study, expression and distribution of Glut‐1 and Glut‐5 proteins were characterized using immunohistochemistry in 76 specimens of benign prostate, 10 specimens of high‐grade intraepithelial neoplasia (HGPIN), and 28 specimens of CaP. In addition, mRNA expression of Glut‐2, Glut‐7, Glut‐9, and Glut‐11 was analyzed in a set of five specimens of benign prostate and CaP. In benign prostate, Glut‐1 localized to the basal cells and to the basolateral membrane of secretory/luminal epithelial cells. Glut‐5, however, localized to the apical membrane of secretory/luminal epithelial cells. In HGPIN, Glut‐1 was immunohistochemically undetectable. Glut‐5, however, localized to the apical membrane of the neoplastic epithelial cells. In CaP, Glut‐1 and Glut‐5, were immunohistochemically undetectable. However, over‐expression of GLUT1 was observed in some specimens of highly proliferative intraductal CaP. Glut‐7, Glut‐9, and Glut‐11 mRNAs were detected in benign prostate and CaP, however, only Glut‐11 mRNA was consistently up‐regulated in CaP compared to benign prostate. Low levels of expression of Glut‐1 protein in the majority of CaP could explain, at least in part, the limited clinical applicability of positron emission tomography using 2‐[18F]‐fluoro‐2‐deoxy‐D‐glucose for imaging CaP. Moreover, expression of Glut‐5 in HGPIN suggested that fructose could be utilized as potential metabolic substrate in HGPIN. Understanding the molecular mechanisms involved in regulation/dysregulation of Gluts in CaP could provide insight in the understanding of hexose metabolism in CaP. J. Cell. Biochem. 113: 553–562, 2012.
PLOS ONE | 2011
Matthew Tanner; R. Charles Welliver; Mengqian Chen; Michael Shtutman; Alejandro Godoy; Gary J. Smith; Badar M. Mian; Ralph Buttyan
The androgen receptor (AR) is expressed in a subset of prostate stromal cells and functional stromal cell AR is required for normal prostate developmental and influences the growth of prostate tumors. Although we are broadly aware of the specifics of the genomic actions of AR in prostate cancer cells, relatively little is known regarding the gene targets of functional AR in prostate stromal cells. Here, we describe a novel human prostate stromal cell model that enabled us to study the effects of AR on gene expression in these cells. The model involves a genetically manipulated variant of immortalized human WPMY-1 prostate stromal cells that overexpresses wildtype AR (WPMY-AR) at a level comparable to LNCaP cells and is responsive to dihydrotestosterone (DHT) stimulation. Use of WPMY-AR cells for gene expression profiling showed that the presence of AR, even in the absence of DHT, significantly altered the gene expression pattern of the cells compared to control (WPMY-Vec) cells. Treatment of WPMY-AR cells, but not WPMY-Vec control cells, with DHT resulted in further changes that affected the expression of 141 genes by 2-fold or greater compared to vehicle treated WPMY-AR cells. Remarkably, DHT significantly downregulated more genes than were upregulated but many of these changes reversed the initial effects of AR overexpression alone on individual genes. The genes most highly effected by DHT treatment were categorized based upon their role in cancer pathways or in cell signaling pathways (transforming growth factor-β, Wnt, Hedgehog and MAP Kinase) thought to be involved in stromal-epithelial crosstalk during prostate or prostate cancer development. DHT treatment of WPMY-AR cells was also sufficient to alter their paracrine potential for prostate cancer cells as conditioned medium from DHT-treated WPMY-AR significantly increased growth of LNCaP cells compared to DHT-treated WPMY-Vec cell conditioned medium.
The Prostate | 2014
Mark A. Titus; Yun Li; Olga Kozyreva; Varun Maher; Alejandro Godoy; Gary J. Smith; James L. Mohler
Currently available 5α‐reductase inhibitors are not completely effective for treatment of benign prostate enlargement, prevention of prostate cancer (CaP), or treatment of advanced castration‐recurrent (CR) CaP. We tested the hypothesis that a novel 5α‐reductase, 5α‐reductase‐3, contributes to residual androgen metabolism, especially in CR‐CaP.
American Journal of Physiology-endocrinology and Metabolism | 2011
Alejandro Godoy; Viviana P. Montecinos; Danny R. Gray; Paula Sotomayor; Jeffrey M. Yau; R. Robert Vethanayagam; Swaroop S. Singh; James L. Mohler; Gary J. Smith
The response of the prostate tissue microenvironment to androgen deprivation (AD) represents a critical component in the treatment of benign prostatic hyperplasia and prostate cancer (CaP). Primary xenografts of human benign and CaP tissue transplanted to immunocompromized SCID mice were used to characterize the response of the prostate vasculature during the initial 14 days of AD. Microvessel density and vascular lumen diameter in the prostate xenografts decreased rapidly after AD, reached a nadir on days 2-4, and recovered between days 4 and 14. The number of apoptotic endothelial cells peaked on day 2 after AD and decreased to precastration levels over days 4-7. Leakage of vascular contents in the interstitial space was apparent between days 1 and 3 after AD; however, the vascular permeability barrier reestablished between days 7 and 14. Expression of vascular endothelial growth factor (VEGF)-A, VEGF receptor-2, and basic fibroblast growth factor protein increased in endothelial cells between days 2 and 4 after AD, which preceded vascular recovery and appeared to be a direct and specific response of the endothelial cells to AD. Lack of comparable upregulation of these genes in primary cultures of human prostate endothelial cells in response to AD suggests a role for paracrine signaling mediated through stromal or epithelial cells. VEGF-A expression by prostate endothelial cells appears to represent a key facilitator of the vascular rebound in human prostate tissue induced by removal of circulating testicular androgens.
PLOS ONE | 2012
Viviana P. Montecinos; Alejandro Godoy; Jennifer Hinklin; R. Robert Vethanayagam; Gary J. Smith
Characterization of the mechanism(s) of androgen-driven human angiogenesis could have significant implications for modeling new forms of anti-angiogenic therapies for CaP and for developing targeted adjuvant therapies to improve efficacy of androgen-deprivation therapy. However, models of angiogenesis by human endothelial cells localized within an intact human prostate tissue architecture are until now extremely limited. This report characterizes the burst of angiogenesis by endogenous human blood vessels in primary xenografts of fresh surgical specimens of benign prostate or prostate cancer (CaP) tissue that occurs between Days 6–14 after transplantation into SCID mice pre-implanted with testosterone pellets. The wave of human angiogenesis was preceded by androgen-mediated up-regulation of VEGF-A expression in the stromal compartment. The neo-vessel network anastomosed to the host mouse vascular system between Days 6–10 post-transplantation, the angiogenic response ceased by Day 15, and by Day 30 the vasculature had matured and stabilized, as indicated by a lack of leakage of serum components into the interstitial tissue space and by association of nascent endothelial cells with mural cells/pericytes. The angiogenic wave was concurrent with the appearance of a reactive stroma phenotype, as determined by staining for α-SMA, Vimentin, Tenascin, Calponin, Desmin and Massons trichrome, but the reactive stroma phenotype appeared to be largely independent of androgen availability. Transplantation-induced angiogenesis by endogenous human endothelial cells present in primary xenografts of benign and malignant human prostate tissue was preceded by induction of androgen-driven expression of VEGF by the prostate stroma, and was concurrent with and the appearance of a reactive stroma phenotype. Androgen-modulated expression of VEGF-A appeared to be a causal regulator of angiogenesis, and possibly of stromal activation, in human prostate xenografts.
The Prostate | 2013
Yue Wu; Alejandro Godoy; Faris Azzouni; John Wilton; Clement Ip; James L. Mohler
Blocking 5α‐reductase‐mediated testosterone conversion to dihydrotestosterone (DHT) with finasteride or dutasteride is the driving hypothesis behind two prostate cancer prevention trials. Factors affecting intracellular androgen levels and the androgen receptor (AR) signaling axis need to be examined systematically in order to fully understand the outcome of interventions using these drugs.